Streetbeat News

MRMD

MariMed Inc

Employees

326

Industry

Medicinal and Botanical Manufacturing

Open

0.16

Mkt cap

59M

Volume

18K

High

0.16

P/E Ratio

-5.17

52-wk high

0.39

Low

0.15

Div yield

N/A

52-wk low

0.14

Senior analyst Pablo Zuanic projects significant growth in Ohio's cannabis market as it transitions to adult-use recreational sales by July 2024. The market could grow fourfold within a year, reaching $2.3 billion. Publicly traded multi-state operators (MSOs) like Vext, Acreage, Cannabist, and Ascend are identified as having high potential for market cap gains.

Portfolio Pulse from Nicolás Jose Rodriguez

May 30, 2024 | 7:07 pm

The article reports on the stock movements of various marijuana-related companies for May 29, 2024. Notable gainers include Global Hemp Group (OTC:GBHPF) with a 218.18% increase and Urban-gro (NASDAQ:UGRO) with a 9.98% increase. Significant losers include The Flowr (OTC:FLWPF) with a 50.00% decrease and Genetic Technologies (NASDAQ:GENE) with a 15.35% decrease.

Portfolio Pulse from Benzinga Insights

May 29, 2024 | 8:30 pm

The article reports on the performance of various cannabis stocks on May 28, 2024. Notable gainers include Heritage Cannabis Holding, Global Compliance, and Urban-gro, while significant losers include Target Group, Elixinol Wellness, and Canopy Growth.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 8:30 pm

The DEA has clarified that THCA must be included in THC concentration levels to comply with the legal definition of hemp, causing concerns within the hemp industry. This comes as Congress revisits cannabinoid regulations in the Farm Bill, with a key House committee passing an amendment to ban most hemp-derived cannabinoids like delta-8 THC. Major cannabis companies, including Curaleaf Holdings, have expressed opposition to these changes.

Portfolio Pulse from Patricio Liddle

May 28, 2024 | 8:26 pm

The cannabis sector experienced mixed movements on May 27, 2024, with notable gains and losses among various companies. Urban-gro (NASDAQ:UGRO), Corbus Pharmaceuticals (NASDAQ:CRBP), Aurora Cannabis (NASDAQ:ACB), and Village Farms Intl (NASDAQ:VFF) saw gains, while Emeren Group (NYSE:SOL), Psychemedics (NASDAQ:PMD), Cara Therapeutics (NASDAQ:CARA), and Genetic Technologies (NASDAQ:GENE) experienced declines.

Portfolio Pulse from Benzinga Insights

May 27, 2024 | 8:30 pm

The article reports on the stock movements of various cannabis-related companies for May 24, 2024. Notable gainers include Corbus Pharmaceuticals (NASDAQ:CRBP) and Genetic Technologies (NASDAQ:GENE), while significant losers include Emeren Group (NYSE:SOL) and Psychemedics (NASDAQ:PMD).

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 8:30 pm

The U.S. House Committee on Agriculture approved an amendment to the new Farm Bill that would eliminate most hemp-derived products, including those with any level of THC. This amendment aims to close a loophole from the 2018 Farm Bill that allowed intoxicating hemp products like Delta-8 THC to be sold. The amendment has sparked a divide between the cannabis and hemp industries, with significant opposition from hemp advocates and some cannabis companies supporting stricter regulations.

Portfolio Pulse from Nina Zdinjak

May 24, 2024 | 12:59 pm

MariMed (OTC:MRMD), a multi-state cannabis operator, is positioned for significant stock gains due to strategic growth plans and the anticipated rescheduling of cannabis. The company reported strong first-quarter 2024 results and stands to benefit from substantial tax savings. Expansion plans in Illinois, Maryland, and Massachusetts are expected to drive future growth.

Portfolio Pulse from Nicolás Jose Rodriguez

May 22, 2024 | 4:50 pm

The article reports on the significant gainers and losers among cannabis stocks on May 14, 2024, highlighting companies that saw notable increases or decreases in their share prices.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 8:30 pm

Cannabis analysts may revise 2024 projections as 10 MSOs beat EBITDA estimates by $37M in Q1. Despite this, full-year estimates only increased by $14M, showing a lag in analyst response. Revenue performance varied, with some companies missing estimates. Despite EBITDA beats, 2024 estimates were cut for six companies. TerrAscend, Ascend, and Green Thumb had significant beats, while MariMed had the largest miss. Margin projections for the year have been adjusted down slightly.

Portfolio Pulse from Nicolás Jose Rodriguez

May 14, 2024 | 1:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.